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Utilities are measures of quality of life that reﬂect the strength of individuals’ preferences or values for a particular
health outcome. As such, utilities represent a measure of disease burden. The aim of this article is to introduce the
concept of utilities to the dermatology community and to present a catalog of dermatology utilities obtained from
direct patient interviews. Our data are based on 236 total subjects from Grady Hospital (Atlanta, GA), Stanford
Medical Center (Palo Alto, CA), and Parkland Hospital (Dallas, TX). The mean time trade-off utilities ranged from
0.640 for blistering disorders to 1.000 for alopecia, cosmetic, and urticaria. The mean utility across all diagnoses
was 0.943. We present utilities for 17 diagnostic categories and discuss the underlying reasons for the signiﬁcant
disease burden that these utilities represent. We also present these dermatology categories relative to
noncutaneous diseases to place the cutaneous utilities in perspective and to compare the burden of disease.
We have demonstrated that skin diseases have considerable burden of disease and provided a preliminary
repository of utility data for future researchers and policy makers.
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In September 2002, the National Institutes of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) sponsored a
workshop entitled, ‘‘Burden of Skin Disease.’’ Experts in
epidemiology, health services research, and quality of life
research, as well as representatives from patient advocacy
groups, met to discuss the various definitions of ‘‘burden,’’
how the definitions of burden pertains to skin diseases, and
the importance of measuring such skin disease burden.
Quality of life (QOL), economic, societal, and family impact
were discussed as aspects of skin disease burden. At the
end of the discussion, all participants agreed that the
dermatology community should derive core measures of
prevalence/incidence, financial costs, and QOL impact of
skin diseases to establish a repository of information that
defines and establishes the magnitude of skin disease
burden. One metric of disease burden, called utilities, was
briefly discussed at the workshop and is the subject of this
article. We seek to introduce the concept of utilities to the
dermatology community and to present a catalog of utilities
obtained from direct patient interviews that may serve as a
reference for policy makers and researchers.
Utilities are quantitative measures of QOL that reflect the
strength of individuals’ preferences or values for a particular
health outcome, also called ‘‘health states’’ by researchers.
Utility scores usually range from 0 to 1, where 0 represents
a preference for a health state equal to that for death and 1
represents a preference for a health state equal to that for
perfect health. For example, two hypothetical patients may
each have a 1-in.-diameter forehead lipoma. The lipomas
are identical. Nevertheless, the first patient is a 16-y-old
woman with an upcoming high school prom whereas the
second patient is a 59-y-old man who cares very little for his
appearance. These two patients will have different prefer-
ences for the health state of the forehead lipoma. The self-
conscious 16-y-old woman may give a utility of 0.76,
indicating that she does not want to have the lipoma and
considers the lipoma quite a burden. On the other hand, the
indifferent 59-y-old man may have a utility of 0.999,
indicating that having the lipoma is similar to being in
perfect health.
Utilities should be distinguished from the other main type
of QOL measure, the health status instrument. Although
both metrics attempt to measure the QOL impact of
particular health states, they capture different aspects in
different ways. Health status instruments describe the
nature of health problems by identifying all the important
features of a disease state such that every aspect of every
dimension is detailed and scored separately (McDowell
and Newell, 1996). These instruments measure and score
dimensions such as physical, functional, psychological, and
social health. The major advantage of the health status
instrument lies in the level of detail provided about QOL.
Abbreviations: CEA, cost-effectiveness analyses; QOL, quality of
life; TTO, time trade-off
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By capturing such detail, health status instruments accu-
rately describe the health status being investigated. These
instruments can also detect the specific QOL dimension
that changes with a therapeutic intervention.
Although health status instruments can be very compre-
hensive and descriptive, they face a problem of balancing
comprehensiveness and generalizability. There are many
disease-specific health status instruments which cover
issues related to a specific disease. For example, Scalpdex
(Chen et al, 2002) is a health status instrument that inquires
into issues particular to scalp psoriasis and seborrheic
dermatitis. Nevertheless, the results of Scalpdex cannot be
compared to results of other disease-specific health status
instruments since the issues are different. There are generic
health status instruments that can be applied across a
variety of diseases, which allow for broad comparisons. The
disadvantage of generic instruments is that they often have
inadequate focus for specific aspects of QOL and may not
detect important issues pertinent to specific diseases. The
other disadvantage of health status instruments is that they
do not reflect the preferences or values of a given individual
or population for a given health state. Because of this,
health status instruments are unsuitable to incorporate QOL
outcomes into cost-effectiveness analyses. Even if a
summary index were provided for a health status instru-
ment, it would be limited to a description of health status,
rather than the preference, or values, associated with the
health status.
Utilities are derived from economic and decision theory
and measured in such a way (see below) that they can be
applied and interpreted across diseases and populations.
Thus, different health states, both skin- and non-skin-
related, can be compared. Utilities focus on the issues
pertinent to the specific disease, so unlike generic health
status measures, they are sensitive to important issues
pertinent to specific diseases. Utilities are also considered
by health economists as the most appropriate metric to
incorporate QOL impact on health states into cost-effec-
tiveness analyses because they reflect preferences and do
not just describe health states. (Gold et al, 1996; Drummond
et al, 1998) They can also be used as outcome measures for
clinical trials (Feeny and Torrance, 1989) and treatment
regimens (Bennett et al, 1991; Nease et al, 1995) and in
individual clinical decision making (Goldstein and Tsevat,
2000).
Utilities may be measured in several different ways. In
general, the interviews are structured such that they ask
individuals to make a choice among alternative lotteries on
quality and quantity of life (Tolley et al, 1994). Two of the
most popular methods are standard gamble and time trade-
off (TTO). Standard gamble asks the subject to choose
between being in their particular health state for the
remainder of their life or to take a gamble. The gamble is
that they would have a certain probability of returning to
perfect health or dying immediately and painlessly (Drum-
mond et al, 1998). The TTO method asks the subject to
choose between a fixed guaranteed life duration in his or
her current health or a shorter duration in the best possible
health. The ratio of the time remaining after the trade to the
life expectancy of the individual is the TTO-derived utility
(Drummond et al, 1998). We prefer the TTO method
because given that most dermatologic problems are often
considered minor health states, we anticipate that the
subjects would give more meaningful responses to the TTO,
in which they were asked to trade off small amounts of time,
than to the standard gamble method, in which they are
asked to trade off low probability risks.
Because utilities are measured by asking subjects how
much time they would trade or how much risk they would
take to not have the disease, utilities are inherently
measures of disease burden. Because policy makers are
increasingly basing health-care resource allocation and
research funding on disease burden, it is imperative that
utilities are available for dermatology. For this purpose, we
report our utility findings from a larger study. In the larger
study, we investigated the feasibility of predicting utilities,
using a mathematical model, from a general dermatology
health status instrument, Skindex (Chren et al, 1997). We
were motivated by the fact that there are overlapping
constructs between utilities and health status instruments
and because utilities are difficult to measure whereas health
status measures are easy to administer. Nevertheless,
in this article, we will report the catalog of utilities to be
used as a preliminary repository of dermatology utility
information.
Results
Demographics We recruited a total of 267 subjects, 77
from Grady Hospital, 106 from Stanford Medical Center,
and 84 from Parkland Hospital. The proportion of subjects
approached who agreed to be interviewed varied by study
site: 97% at Grady Hospital, 25% at Stanford Medical
Center, and 67% at Parkland Hospital. Language barrier
was the primary reason for potential subjects to decline at
Parkland Hospital. The Stanford and Grady nonparticipants
did not give reasons. Completion rates were 90% at Grady
(8 did not complete the TTO portion of the interview), 100%
at Stanford, and 98% at Parkland (2 did not complete 8 or
more Skindex items). Noncompleters were excluded from
the final analysis. As usual for utility studies, we also
excluded subjects who did not understand the TTO or who
gave inconsistent responses to the utility elicitation ques-
tions (n¼6). For example, some subjects rated their current
health utility including skin problems greater than their skin-
only utility (n¼4). We also eliminated one subject who
scored all the Skindex questions 0.75 or higher but gave a
utility score of 0.000, indicating a lack of understanding.
Thus, the final data included 250 subjects (68 from Grady,
102 from Stanford, and 80 from Parkland).
Subjects represented a variety of ethnic and demo-
graphic groups, although these varied by site (Table I). We
found that the differences in age across sites were
statistically significant (po0.001, by ANOVA). Pairwise
comparisons revealed that the population at Grady was
significantly younger than the populations at the other two
sites (po0.001). We found no significant difference in sex
across sites (p¼ 0.19, Pearson’s chi-square analysis). There
was a significant difference in race across sites (po0.001),
when categorized as ‘‘white’’ and ‘‘nonwhite’’; each site was
significantly different from each other (po0.001, Pearson’s
chi-square analysis). Most subjects from Grady were
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African-American whereas those from Stanford were Cau-
casian; subjects from Parkland were relatively evenly split
between these two race groups. We found a significant
difference across site in education (po0.001, Kruskal–
Wallis test). Pairwise analyses revealed that each site was
significantly different from each other, with Stanford sub-
jects having the most education and Parkland subjects
having the least (po0.001, Wilcoxon rank sum test). We
found a significant difference across sites for income
(po0.001, ANOVA). The population at Stanford had a signifi-
cantly (po0.001) higher annual income than those at each
of the other two sites. These differences were expected,
because they reflect the underlying patient populations.
Diagnostic categories We asked both patients and der-
matologists to list the diagnosis leading to that visit. Where
the patient and the dermatologist differed in the diagnosis,
we report the diagnosis given by the dermatologists. We
excluded 14 subjects who had multiple dermatologic
diagnoses because our purpose is to present a catalog of
utilities by diagnostic categories and specific diagnoses.
Thus, the final analysis was based on the remaining 236
subjects.
We sorted the diagnoses into 17 broad diagnostic
categories (Table II). Many of these categories reflected
the morphologic similarities among various specific clinical
entities. For example, we classified acne vulgaris, acne
rosacea, and milia as ‘‘acneiform.’’ The category ‘‘neoplasia
of uncertain behavior’’ reflects a health state where the
dermatologist biopsied a particular lesion and the patients
were uncertain about the diagnosis at the time of the
interview. Because we elicited the utility before the subject
had any definitive diagnosis, the utility given by the patient
reflects the anxiety of an unknown, potentially harmful condi-
tion. For four categories, each with only one subject, we
could not determine a broader diagnostic category. These
were alopecia, cosmetic (subject wanted laser resurfacing),
sarcoid, and urticaria.
Several other diagnostic categories also had small
numbers of subjects. We present these categories in Table
II to demonstrate the wide range in utility. Nevertheless, we
will focus our attention on the top six categories (papulo-
squamous, infection-infestation, dermatitis, acneiform, neo-
plasm of uncertain behavior, and benign tumor), which
collectively represent 73% of the study population.
Utilities The mean TTO utilities ranged from 0.640 for
blistering disorders to 1.000 for alopecia, cosmetic, and
urticaria (Table II). The mean utility across all diagnoses was
0.943. Of note, we reported the utilities for basal cell and
squamous cell carcinomas as a combined category in Table
II because many dermatologists and patients group such
skin cancers collectively as nonmelanoma skin cancers.
We also analyzed utilities within each of these broad
categories for specific diagnoses with five or more subjects
(Table III). Diseases with fewer than five subjects that we do
not report data include pruritus, lichen planus, pyoderma
gangrenosa, insect bites, folliculitis, furuncle, hidradenitis
suppurativa, tinea, tinea versicolor, seborrheic dermatitis,
stasis dermatitis, pityriasis rosea, chelitis, perioral derma-
titis, drug eruption, hand dermatitis, melasma, rule-out
squamous cell carcinoma, dermatofibroma, seborrheic
keratosis, keloid, basal cell carcinoma, squamous cell
carcinoma, discoid lupus, bullous pemphigoid, epidermo-
lysis bullosa acquisita, B cell lymphoma, stasis ulcer, herpes
simplex, impetigo, actinic dermatitis, keratosis pilaris,
Table I. Demographics of subjects included in the analysis
Variable Grady Hospital Stanford Medical Center Parkland Hospital Combined
Number of subjects (% recruited) 68 (88) 102 (96) 80 (95) 250 (94)
Age (years)a 36 (12) 50 (18) 49 (15) 46 (17)
Sexb
Male 31 (46) 49 (48) 28 (35) 108 (43)
Female 37 (54) 53 (52) 52 (65) 142 (57)
Raceb
Caucasian 5 (7) 83 (81) 35 (44) 123 (49)
African-American 57 (84) 1 (1) 33 (41) 92 (37)
Other (includes Latino and Asian persons) 6 (9) 18 (18) 12 (15) 27 (11)
Educationb
Primary school 2 (3) 2 (2) 16 (20) 20 (8)
High school 41 (60) 7 (7) 44 (55) 92 (37)
College 22 (32) 44 (43) 12 (15) 78 (31)
Postgraduate 3 (4) 49 (48) 3 (4) 55 (22)
Incomea $18,860 ($18,302) $90,289 ($58,341) $12,250 ($13,021) $44,691 ($53,055)
Number of subjects (%) 68 (100) 95 (93) 80 (100) 243 (97)
aMean (SD).
bNumber of subjects (%).
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Table II. Utilities for diagnostic categories
Diagnosis categorya Number (% of total) Mean utility SD Median utility
Bullous diseases 2 (1) 0.640 0.198 0.640
Lymphoma 6 (2) 0.820 0.290 1.000
Pruritus and related conditions 9 (4) 0.915 0.145 0.966
Papulosquamous 13 (5) 0.919 0.114 0.971
Ulcers 4 (2) 0.923 0.154 1.000
Infection-infestation 35 (14) 0.933 0.189 1.000
Dermatitis 52 (21) 0.939 0.098 0.986
Acneiform 30 (12) 0.940 0.120 0.990
Sarcoid 1 (0.4) 0.949 — 0.949
Dyschromia 14 (6) 0.966 0.103 1.000
Neoplasm of uncertain behavior 35 (14) 0.971 0.047 0.996
Melanoma 2 (1) 0.972 0.039 0.972
Benign tumor 17 (7) 0.974 0.054 1.000
Nonmelanoma skin cancer 8 (3) 0.976 0.052 1.000
Collagen vascular disease 4 (2) 0.979 0.029 0.989
Cyst 8 (3) 0.980 0.038 1.000
Actinic keratosis 9 (4) 0.981 0.056 1.000
Alopecia 1 (0.4) 0.998 — 0.998
Cosmetic 1 (0.4) 1.000 — 1.000
Urticaria 1 (0.4) 1.000 — 1.000
All diagnoses 236 (100) 0.943 0.124 1.000
aDiagnostic categories are listed in order of ascending mean utilities. Categories marked with asterisks comprise 73% of the study population.
Table III. Utilities of speciﬁc diagnoses
Category Diagnosis Number Mean utility SD Median utility
Lymphoma Mycosis fungoides 5 0.867 0.298 1.000
Pruritus and related conditions Prurigo nodularis 5 0.943 0.064 0.966
Papulosquamous Psoriasis 11 0.907 0.121 0.966
Infection-infestations Condyloma 5 0.706 0.434 0.958
Onychomycosis 6 0.988 0.018 0.997
Warts 7 0.986 0.035 0.999
Dermatitis Atopic dermatitis 5 0.890 0.134 0.915
Contact dermatitis 10 0.898 0.159 0.984
Eczema and xerosis 11 0.968 0.055 1.000
Lichen simplex chronicus 5 0.987 0.022 1.000
Acneiform Acne vulgaris 28 0.938 0.124 0.990
Dyschromia PIH 6 1.000 0.000 1.000
Neoplasm of uncertain behavior Rule-out basal cell carcinoma 8 0.974 0.040 0.997
Rule-out nonmelanoma skin cancer 10 0.979 0.036 0.997
Rule-out melanoma and dysplastic nevi 11 0.979 0.026 0.988
Benign tumor Acrochordon 7 0.962 0.074 1.000
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pityriasis rubra pilaris, Hailey-Hailey disease, acne rosacea,
milia, poikiloderma, lipoma, and fibrous papule. We also do
not report utilities for four subjects with ‘‘neoplasm of un-
certain behavior’’: one with Kaposi’s sarcoma, two subjects
for whom the differential diagnosis was not provided, and
one subject for whom it was unclear if he was informed of
his diagnosis before that particular appointment. We
encourage future investigators to contact us for unreported
data since this catalog represents a work in progress.
Comparison of utilities between sites To ascertain any
bias owing to the different interviewers between sites, we
compared the overall mean utility scores among the three
sites. There was no significant difference (p¼0.35, ANOVA).
We also compared utility scores across the three sites for
several common diagnoses: acne, psoriasis, dermatitis,
benign growth, and nonmelanoma skin cancers/actinic
keratoses. Again, we did not find significant differences
among sites for these diagnoses (p¼0.79, 0.5, 0.60, 0.50,
and 0.41, respectively).
Discussion
Although other studies have purported to measure utilities
in dermatology, only two published articles thus far have
followed rigorous utility assessment methods: Zug et al
(1995) and Lundberg et al (1999) elicited time trade-off and
standard gamble utilities for psoriasis. Lundberg et al (1999)
also reported utilities for atopic eczema. In addition to
psoriasis and atopic eczema, we have assembled the most
comprehensive catalog of dermatologic utilities to date.
The data reflect some of the most common dermatoses
observed in a general dermatology clinic. Our multisite
study design ensured a wide variety of subjects with a
diverse socioeconomic and geographic range.
This catalog provides a preliminary repository of utility
data for both policy makers and researchers. Policy makers
interested in disease burden measures may consider
dermatology problems to be minor and have relatively low
disease burden. If that were true, we would have found
utilities to cluster near 1.000 (perfect health). Instead, we
found that although close to half of the utility scores were
greater than 0.95, the overall mean utility was 0.943 and the
lowest utility was 0.640 for bullous diseases.
To put these utility values in perspective and to compare
the burden of skin diseases to noncutaneous diseases, we
include a table (Table IV) comparing some of our findings to
utilities of nondermatologic health states. Although each
study used slightly different elicitation methods, the com-
parison provides some interesting insights. For example, it
is not surprising that the burden of bullous diseases (0.640)
were comparable to that of kidney diseases (0.740) or AIDS
(0.791) because these conditions are incurable and are
associated with a considerable risk of morbidity and
mortality. It is also reasonable that benign conditions such
as warts (0.986) and acne (0.938) have high utility scores.
The relatively high utility for mycoses fungoides (0.867) can
be understood if the diseases were of the patch, rather than
Table IV. Time trade-off derived utilities of health states
Health condition Mean utility SD Median utility TTO method
Prostate cancer, metastatic
(Krahn et al, 1994)
0.58 NAa NA ‘‘Gambler,’’ an automated graphical utility assessment
tool; from a group of 10 physicians, including urologists,
radiation oncologists, and internists
Bullous diseases 0.640 0.1975 0.6397 See Materials and Methods
Minor AIDS-defining illness
(Bayoumi and Redelmeier, 1999)
0.65 0.33 0.75 Verbal interview, no props
Mild hip osteoarthritis
(Laupacis et al, 1993)
0.69 0.27 NA Specific interviewing methods not detailed
Condyloma 0.706 0.4335 0.9578 See Materials and Methods
Kidney disease
(Hornberger et al, 1992)
0.740 NA NA Verbal interview, no props; life expectancy was patient’s
own value
AIDS (Tsevat et al, 1996) 0.790 0.31 NA Verbal interview, no props, used ‘‘ping-pong’’ method; did
not state origin of life expectancy values
Symptomatic HIV
(Bayoumi and Redelmeier, 1999)
0.81 0.27 0.96 Verbal interview, no props
Atrial fibrillation
(Gage et al, 1995)
0.823 0.250 0.923 Computer-based utility elicitation tool, U-titer
Mycosis fungoides 0.867 0.2981 1.0000 See Materials and Methods
HIV without symptoms
(Sanders et al, 1994)
0.870 0.29 NA Computer-based utility elicitation tool, U-titer
Breast cancer (Grann et al, 1998) 0.89 NA NA Verbal interview; questionnaire for health states
Acne vulgaris 0.938 0.124 0.990 See Materials and Methods
Warts 0.986 0.035 0.999 See Materials and Methods
aNA, not available.
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of the nodular stage. It is harder to understand why the
utility for condyloma accuminata (0.706) would be so low,
but perhaps the stigmata and recurrent nature of this
problem is an explanation. Also, with two of the sites
representing county hospitals where many patients delay
their medical care, the condyloma seen there may be more
advanced and cause more morbidity than otherwise
expected. Readers are referred to an excellent reference
cataloging 1000 utilities of other diseases (Tengs and
Wallace, 2000).
Of the six diagnostic groups composing up 73% of the
study population, the utilities range from 0.919 (papulo-
squamous) to 0.974 (benign tumor). To gain intuition into
these values, we take a hypothetical man with 35 y of
life expectancy. If the man gives a utility of 0.919 for a
papulosquamous process, this would mean that he would
be willing to trade 2.8 y of his life to have the remainder of
his life without the papulosquamous process. Similarly, he
would be willing to trade 0.9 y to not have a benign tumor.
From this perspective, the reader could reasonably agree
that the skin processes in these main diagnostic groups
represent a significant disease burden. It is not difficult to
discern reasons underlying the burden.
The papulosquamous category consists mainly of psor-
iasis (mean utility, 0.907; Table III). It is not surprising to find
such a low mean utility for psoriasis given the accompany-
ing pruritus, scaling, inflammation, and potential social
stigma (Updike, 1976). The infection-infestation category
(0.933) includes condyloma, which has been discussed
above, and tinea, which can be quite pruritic. Given the
chronic, symptomatic nature of many types of dermatitis
(0.939), especially atopic and contact dermatitis, it is
again not surprising that these patients indicated a
significant burden of disease. The mean utility for the
acneiform category (0.940) can be explained by the fact
that most acne occurs on the face and may affect self-
esteem. The mean utility for the category of neoplasm of
uncertain behavior (0.971) reflects the anxiety of an
unknown, potentially harmful condition. The category of
benign tumor includes dermatofibromas, acrochordons,
and seborrheic keratoses, all of which can be bothersome
to the patient.
As demonstrated, the catalog of utilities provides insight
into the burden of skin disease. The catalog will also be
useful as a reference for future cost-effectiveness analyses
because empirical elicitation of utilities is time-consuming
and labor-intensive. Nevertheless, in using our data,
researchers need to be aware of several limitations. The
main limitation is that many disease categories had
relatively few subjects. Although the standard deviation
gives insight to the distribution of utility scores, our data are
insufficient to speculate about the characteristics of an
entire patient population.
The relative paucity of subjects in certain disease
categories may potentially threaten the face validity of our
data. Nevertheless, our mean utility (0.907) for psoriasis is
comparable to that of Zug et al (1995) (mild psoriasis, 0.89;
moderate, 0.79; and severe, 0.59) and Lundberg et al (1999)
(0.88). Our atopic dermatitis utility (0.890) is slightly lower
than that of Lundberg’s eczema (0.93), but our ‘‘eczema and
xerosis’’ category is higher (0.968) and may compensate for
the atopic dermatitis utility if Lundberg consolidated both
categories.
To account for the variability in data from the small
sample sizes, future investigators should use the standard
deviation data to derive upper and lower limits of utility for
their studies. For example, in cost-effectiveness analyses
(CEA), a sensitivity analysis is performed where all variables
are varied within reasonable clinical parameters to see if the
results of the CEA are sensitive to those variables. Utilities
should be varied as described above to see if the CEA is
sensitive to utilities. If so, investigators should report that
their findings are not robust and may want to consider
measuring utilities for their study empirically. We also
encourage future investigators to contact us for unreported
data as well as updates in our reported data because this
catalog represents a work in progress.
Of note, to obtain an estimate of the number of patients
required to achieve a given level of accuracy of the mean
utilities, we calculated 95% confidence intervals (CI) of
varying widths for mean utility. We based these calculations
on the mean utility and standard deviation across all
diagnoses (0.94  0.07). Those diagnoses with zero vari-
ance were not included in the calculations (see Table III).
Table V presents the number of subjects required to obtain
95% CI of width 0.1 (e.g., 0.8–0.9), 0.05, 0.02, and 0.01.
Although the average across all utilities is a fair
representation of most of the diseases, a few have much
larger variances such as condyloma and mycosis fun-
goides. For condyloma, the number of patients required to
achieve a 95% CI of width 0.1 would be 250; for mycosis
fungoides the number would be 140.
The second limitation is that we did not characterize
disease severity and thus are unable to comment on the
impact of disease severity on our measured utilities. For
example, there are only two patients in the melanoma
category; it is possible that one patient had thin mela-
noma with a high utility whereas the other had thick
melanoma with a low utility, averaging to 0.972, or both
patients could have medium-thickness melanoma with the
same average utility. For researchers to compare two
therapies via CEA, they need the utilities of all possible
outcomes of the therapies. Thus, they need the utilities of all
different levels of clinical severities. Although we do not
provide this information in this catalog, we encourage
researchers to interpret our data as references, from which
they can extrapolate utilities for different clinical severity
states. Because our utility catalog represents empirical data
elicited directly from dermatology patients, the data are a
better source for utility estimates than extrapolation from
nondermatologic diseases.
TableV. Number of subjects required to obtain 95% CI for a
mean utility of 0.94
95% CI width Number
0.10 12
0.05 23
0.02 55
0.01 108
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The melanoma example brings to light a potential
selection bias in the utilities of cancer patients in our study.
There are specialty melanoma clinics at Parkland and
Stanford, so subjects seen in the general dermatology
clinic either were not yet referred to the specialty clinics
or were returning for follow-up after being in long-term
remission. Because we approached the subjects before
their appointment, new patients may not have realized the
seriousness of their condition, and thus their utilities may
not reflect these concerns.
Finally, readers should note that by using average
population-based life expectancy to calculate the TTO
utilities, we may have overestimated the life expectancy for
people with severe, life-threatening diseases such as
collagen vascular disease, malignancy, pyoderma gang-
renosum, and autoimmune blistering diseases. We chose to
use population-based life expectancies because we were
enrolling consecutive patients where we could not antici-
pate their disease. With population life tables, we would
expect the life expectancies to reflect an average across
people with severe diseases and healthy people. Never-
theless, the life expectancy issue raises a more controver-
sial philosophical issue: should the ‘‘best possible health’’
option be presented to individuals with the time frame of
their disease or the time frame of the average person in
‘‘best possible health’’? Currently, there is no consensus on
the best approach and we do not feel that there are any
a priori reasons to think one is better than the other, but
encourage future investigation to explore the issue.
Despite these limitations, we are confident that our
catalog of utilities represents a useful information repository
of skin disease burden. Future work should be encouraged
to verify the accuracy of these data with adequate sample
size. We also encourage future investigators to document
clinical severity for future utility assessment studies.
Materials and Methods
Subjects and setting We recruited subjects from general derma-
tology clinics at Stanford Medical Center (Stanford, CA), Grady
Hospital (Atlanta, GA), and Parkland Hospital (Dallas, TX),
representing diverse racial, geographic, and socioeconomic
groups. We obtained approval from the institutional review board
of each respective institution and informed consent from all
subjects. The study adhered to the Declaration of Helsinki
Guidelines for human subject research. The interviewers recruited
subjects as follows: for Grady and Parkland Hospitals, the
interviewers consulted the schedule of appointments at each
clinic and called each subject from the waiting room in a sequen-
tial manner until the first person agreed to participate. After the
3-min interview, the interviewer recruited the next consenting
subject on the roster. At Stanford Medical Center, the 30-min
interviews were scheduled by telephone calls in the days
preceding the clinic visit.
We excluded subjects who could not converse with the
interviewer owing to language, physical, or cognitive barriers. We
also excluded subjects who could not see the prop used (Fig 1) for
utility elicitation. Subjects who had difficulty understanding the
utility elicitation procedure were asked to explain, in their own
words, the purpose of the questions. If subjects were unable to
Figure1
Prop for utility assessment using time trade-off. The
prop consisted of two boards. Interviewers showed the
board on the top (Board 1) to the subject first, querying her
preferences between option A or option B. Ages and
corresponding life expectancies were printed on levers that
were pulled to display the subject’s information through the
windows in option A. Option B was controlled using two
concentric wheels. The wheels were rotated to adjust the
numbers displayed in the windows of option B. A panel was
flipped up and down to reveal the decreasing extremes of
option B, thereby achieving the ping-pong technique. The
interview would continue until options A and B were the
same to the subject. The interviewers used the board on
the bottom (Board 2) to fine tune the subject’s time trade-
off preference to the level of days. The numbers displayed
in the windows were adjusted by pulling on printed levers.
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give a satisfactory answer, the interviewer outlined a standard
explanation. Subjects who still did not understand the utility
elicitation procedure were excluded.
Data collection One interviewer administered all questionnaires
at a given site. One of the authors (S.C.C.) trained all three
interviewers to ensure interinterviewer consistency. The inter-
viewers collected data on age, sex, ethnicity, skin condition, and
comorbid conditions at the beginning of the interview. The subjects
next completed the Skindex questionnaire and the utility elicitation,
each of which was interviewer-administered. Because income and
education are sensitive topics, we reserved these questions for the
end of the interview.
Utility elicitation We used the TTO technique for utility elicitation
(Stalmeier et al, 2001). With this method, subjects are asked to
choose between a fixed guaranteed life duration in their current
health or a shorter duration in best possible health. We varied the
duration spent in best possible health to find the trade-off at which
individuals are indifferent between the two choices. The ratio of
time remaining after the trade to the guaranteed life duration in
current health yields the TTO utility. We obtained the life expec-
tancy from tables of the expectation of life in the United States
based on age and sex (Centers for Disease Control and Pre-
vention, 1996). We told subjects that these were average life
expectancies for a person of their age. To separate the utility for
subjects’ skin condition from other health-related problems, we
asked subjects to provide separate ratings for the two health
states: (1) their current health condition (skin and other comorbid-
ities) and (2) their current skin condition independent from
comorbid conditions (Harris and Nease, 1997).
We administered the TTO questions with semiscripted inter-
views (Appendix I) and physical props (Fig 1). (Dolan et al, 1996)
The prop consisted of two boards. The first board offered a choice
between option (A), remaining life-years in current health, or option
(B), a shorter life duration without any skin problems or comorbid
conditions. To prevent anchoring effects, the allotted time in (B)
was varied in a ping-pong fashion (Dolan et al, 1996) until the
subject was indifferent between (A) and (B). The ping-pong method
involves starting at one extreme (e.g., trading no time) and then
presenting the other extreme (e.g., trading the remainder of life)
and alternating at the two ends with more/less time traded
(Appendix I). The second board fine-tuned the time trade-off into
months, weeks, and days. The entire process was then repeated,
with the difference that (B) was defined as life without skin
problems but with other current health problems. To avoid framing
effects (Blumenschein and Johannesson, 1998), the interviewers
phrased option (B) to reflect both a loss and a gain: subjects would
lose a certain amount of lifetime to gain the remaining lifetime in
health without the skin problem. Before the actual utility elicitation,
the subjects underwent an example evaluating the health state of
paralysis to become familiar with the prop and the technique.
Statistical analysis We used the SAS statistical software package
(SAS Institute, 1989–1996) for all analyses. The statistical methods
were standard parametric, nonparametric, and chi-square fre-
quency procedures specified in the presentation of the results.
Nominal p values are given, without allowance for multiplicity.
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Appendix I: Example of the Time Trade-off Utility
Elicitation In this example, the subject is 30-y-old man
with severe penile condyloma. He has an average life
expectancy of 45 y. Our interviewers were given a script and
instructed to guide the subject as follows:
Interviewer Your first choice is whether you want to live the
rest of your life for 45 years with your condyloma or live
without your condyloma for 45 years and give up nothing.
Which do you prefer or are the choices the same?
Subject I choose option B where I would live 45 more years
without my condyloma.
Interviewer Your next choice is whether you want to live the
rest of your life for 45 years with your condyloma or live
without your condyloma for 0 years and give up 45 years. In
other words, you’d die this year without any pain or suffering.
Which do you prefer or are the choices the same to you?
Subject I do not want to die now. I choose option A, to live
45 more years with my condyloma.
Interviewer Your next choice is whether you want to live
the rest of your life for 45 years with your condyloma or live
without your condyloma for 44 years and give up 1 years
of your life. Which do you prefer or are the choices the same
to you?
Subject I would want to give up 1 year of life to have 44
years without my condyloma. I choose option B.
Interviewer Your next choice is whether you want to live
the rest of your life for 45 years with your condyloma or live
without your condyloma for 1 year and give up 44 years
of your life. Which do you prefer or are the choices the same
to you?
Subject I do not want to give up 44 years of my life. I
choose to live 45 more years with my condyloma.
Interviewer Your next choice is whether you want to live
the rest of your life for 45 years with your condyloma or live
without your condyloma for 43 years and give up 2 years
of your life. Which do you prefer or are the choices the same
to you?
Subject I do not want to give up 2 years of my life. I choose
option A, living 45 years with my condyloma.
Interviewer So this means that you are willing to give up 1
year but not 2 years, right? Now we want to see if we can
break this down into months, weeks, or days.
The interviewer would use the second board and
continue in the same fashion until the number of years,
months, weeks, and days that the subject would be willing
to trade was ascertained.
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